AIDS Treatment News logo      

August 10, 2010

Analysis: HIV generics under threat from tighter patenting rules

PlusNews: "Of particular concern are negotiations around a "Broad-based Trade and Investment Agreement" between India and the EU, due to be completed by December 2010. Activists fear such an agreement may impose TRIPS-plus-type conditions on India's manufacture and export of generic medicines.

"Shifting away from generic competition would put the power of price-fixing back into the hands of 'big pharma' and make ARVs unaffordable again," said Gilles van Cutsem, project coordinator for Médecins Sans Frontières in the South African township of Khayelitshan."